Results 61 to 70 of about 19,663 (194)
, 2014 Aims: ID1 is an important component of the MET-SRC signaling pathway, which is a regulator of cell migration and invasion. We hypothesized that the ALK/MET inhibitor crizotinib inhibits migration via MET-SRC-ID1, rather than ALK.
Rothschild, Sacha I. +5 more
core +1 more source
Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
Case Reports in Oncology, 2013 We report the case of a 50-year-old male former smoker. He was diagnosed as having lung adenocarcinoma and treated with induction chemoradiation therapy followed by surgery and adjuvant chemotherapy.
Yuka Kuriyama +5 more
doaj +1 more source
Allergy, EarlyView.ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud +14 more
wiley +1 more source
Severe bradycardia associated with crizotinib
, 2017 Crizotinib is a multitarget tyrosine kinase inhibitor used in treating non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene mutation. Common and well-known adverse effects include gastrointestinal disturbance, dizziness, fatigue,
Bernard Cheung +5 more
core +1 more source
Cancer Science, EarlyView.This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato +5 more
wiley +1 more source
Ultra-deep mutational analysis of NPM-ALK and possible implications on target therapy in anaplastic large cell lymphoma of childhood [PDF]
, 2013 Anaplastic Large Cell Lymphoma (ALCL) represents a distinct subset of aggressive T-cell non-Hodgkin lymphoma (NHL) accounting for about 3% of adult NHL and 10 to 15% of childhood lymphomas.
Lovisa, Federica
core
Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy
Cancer Science, EarlyView.This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang +6 more
wiley +1 more source
Comparison of actions of crizotinib or alectinib on firing rate.
, 2015 Category S: both crizotinib and alectinib had the same effect on the firing rate. Category O: the drugs had opposite effects on the firing rate. Category C: only the effect of crizotinib was significant.
Makoto Kaneda (168546) +5 more
core +1 more source
European Journal of Haematology, EarlyView.ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
Histopathology, EarlyView.Poorly differentiated lung adenocarcinomas with concurrent anaplastic lymphoma kinase (ALK) and CD30 expression closely mimic ALK‐positive anaplastic large‐cell lymphoma, creating a significant diagnostic pitfall. Accurate classification requires comprehensive integration of clinical, radiologic, morphologic, immunophenotypic and molecular findings ...
Jietian Jin +6 more
wiley +1 more source